(Q40575818)

English

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

scientific article published on 4 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide (English)

1 reference

Europe PubMed Central

21 September 2017

apoptotic process

0 references

author name string

H Jiang

1

1 reference

Europe PubMed Central

21 September 2017

C Acharya

2

1 reference

Europe PubMed Central

21 September 2017

G An

3

1 reference

Europe PubMed Central

21 September 2017

M Zhong

4

1 reference

Europe PubMed Central

21 September 2017

X Feng

5

1 reference

Europe PubMed Central

21 September 2017

L Wang

6

1 reference

Europe PubMed Central

21 September 2017

N Dasilva

7

1 reference

Europe PubMed Central

21 September 2017

Z Song

8

1 reference

Europe PubMed Central

21 September 2017

G Yang

9

1 reference

Europe PubMed Central

21 September 2017

F Adrian

10

1 reference

Europe PubMed Central

21 September 2017

L Qiu

11

1 reference

Europe PubMed Central

21 September 2017

P Richardson

12

1 reference

Europe PubMed Central

21 September 2017

N C Munshi

13

1 reference

Europe PubMed Central

21 September 2017

Y-T Tai

14

1 reference

Europe PubMed Central

21 September 2017

K C Anderson

15

1 reference

Europe PubMed Central

21 September 2017

publication date

4 September 2015

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

30

1 reference

Europe PubMed Central

21 September 2017

2

1 reference

Europe PubMed Central

21 September 2017

399-408

1 reference

Europe PubMed Central

21 September 2017

https://scigraph.springernature.com/pub.10.1038/leu.2015.240

0 references

Therapeutic advancements in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Current treatment landscape for relapsed and/or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Choosing treatment options for patients with relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Antibody-based therapies in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Elotuzumab for the treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Daratumumab granted breakthrough drug status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

The development of potential antibody-based therapies for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

CD38/CD19: a lipid raft-dependent signaling complex in human B cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Lysosomal cell death at a glance.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

CD20-mediated apoptosis: signalling through lipid rafts

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Combating apoptosis and multidrug resistant cancers by targeting lysosomes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.240

21 January 2018

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26338273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical stage-depending decrease of NK cell activity in multiple myeloma patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26338273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 haploinsufficiency and functional abnormalities in multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26338273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26338273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26338273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26338273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2015.240

1 reference

Europe PubMed Central

21 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40575818&oldid=1903213151"